Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Helperby Therapeutics
Helperby Therapeutics
Activities:
Research & Development
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Tabletability, compactability and compressibility: What’s the difference?
To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
Indian government bans three medicines owing to health risks
Decision follows strong stand on suspending marketing of all drugs prohibited for sale in other countries, including the US, UK, EU and Australia
Berry Global invests to increase production capacity for healthcare products
Berry Global Group has invested in additional assets and manufacturing capabilities to increase its healthcare production capacity by up to 30% across three of its European sites
Effective ways to optimise heat exchangers
Heat exchangers are used within a wide range of process industries as a way to transfer heat between two fluid streams across a medium in an energy conservative way
Upcoming event
BIO International Convention Digital
3-6 June, 2024 | Convention | San Diego, US
See all
Related Content
Research & Development
How can we save medicine from superbug disaster?
Two leading research teams to collaborate on new fast track antibiotic therapies, with an aim to bring new sophisticated combination therapies to market in a much-reduced timescale
Ingredients
Two of the world’s leading research teams to collaborate on new fast track antibiotic therapies
Aiming to bring new sophisticated combination therapies to market in a much reduced timescale
Regulatory
Treatments to solve global antibiotic crisis may reach the market in 2020
Helperby Therapeutics has developed the first sustainable solution to combat all three deadly critical priority pathogens named by World Health Organisation (WHO)<sup>1</sup>
Research & Development
Helperby Therapeutics and Cadila sign antibiotic drug resistance agreement
Cadila will take a new Helperby compound through Phase III trials, approvals and into commercialisation
Subscribe now